FDA Digital Health Innovation Plan: SaMD Approvals Impact

The FDA Digital Health Innovation Plan streamlines Software as a Medical Device (SaMD) approvals through the Digital Health Center of Excellence and new AI/ML guidance, accelerating safe innovation while ensuring patient safety.

Key Takeaways

The FDA established the Digital Health Center of Excellence (DHCoE) on September 22, 2020, to advance digital health innovation and provide centralized regulatory guidance.
The FDA released its AI/ML-Based SaMD Action Plan on January 12, 2021, outlining a framework for regulating adaptive machine learning-enabled medical devices.
Final guidance on Predetermined Change Control Plans (PCCP) issued December 4, 2024, allows manufacturers to pre-approve planned software modifications without additional submissions.
SaMD is defined by the IMDRF as software intended for medical purposes that functions independently of hardware medical devices.
The FDA reviews SaMD through 510(k), De Novo, or PMA pathways depending on risk classification.

What Is Software as a Medical Device?

Software as a Medical Device (SaMD) is defined by the International Medical Device Regulators Forum (IMDRF) and adopted by the FDA as software intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device. This definition distinguishes SaMD from software integrated into hardware (Software in a Medical Device, or SiMD) and from software used only for manufacturing or maintenance purposes.

SaMD includes mobile apps that diagnose medical conditions, software that analyzes medical images, and algorithms that recommend treatment plans. The FDA classifies SaMD based on the seriousness of the healthcare situation and the significance of the information provided to the healthcare decision.

When Did the FDA Launch the Digital Health Center of Excellence?

The FDA established the Digital Health Center of Excellence (DHCoE) on September 22, 2020, as part of the planned evolution of the Digital Health Program in the Center for Devices and Radiological Health (CDRH). The DHCoE serves as a central resource for digital health technologies, providing expertise and guidance to developers, stakeholders, and FDA staff.

The DHCoE aims to foster responsible and high-quality digital health innovation, align digital health efforts across the FDA, and advance regulatory science in digital health technologies. Bakul Patel was appointed as the first director of the DHCoE. The center coordinates with other FDA centers including CBER, CDER, and OCP to ensure consistent approaches to digital health regulation.

How Is the FDA Regulating AI and Machine Learning in SaMD?

The FDA released its AI/ML-Based Software as a Medical Device Action Plan on January 12, 2021, outlining strategies for regulating artificial intelligence and machine learning-enabled medical devices. This plan addresses the unique challenges posed by adaptive algorithms that can change their performance through learning.

A key component of the FDA's approach is the Predetermined Change Control Plan (PCCP). The FDA issued draft guidance in April 2023 and finalized it on December 4, 2024. The final guidance provides recommendations for including PCCPs in marketing submissions for AI-enabled devices.

The PCCP framework allows manufacturers to describe anticipated modifications to their devices in advance. The plan includes SaMD Pre-Specifications (SPS) defining anticipated changes and an Algorithm Change Protocol (ACP) describing the methods to implement changes safely. This approach enables iterative improvements without requiring additional marketing submissions for each modification.

What Premarket Pathways Does the FDA Use for SaMD?

The FDA reviews SaMD through traditional premarket pathways based on risk classification:

FDA SaMD Premarket Review Pathways
Pathway	Application Type	Typical Timeline
510(k)	Premarket Notification	90 days FDA review
De Novo	Classification Request	120-150 days FDA review
PMA	Premarket Approval	180 days FDA review

The FDA's Center for Devices and Radiological Health (CDRH) plays a central role in overseeing SaMD regulation. Lower-risk SaMD may qualify for the 510(k) pathway if a substantially equivalent predicate device exists. Novel SaMD without predicates typically requires the De Novo pathway. High-risk SaMD that support life-sustaining treatment may require Premarket Approval.

What Is the Market Impact of FDA Digital Health Initiatives?

The FDA Digital Health Innovation Plan has significantly impacted the market for medical devices and digital health solutions. By streamlining SaMD approvals, the FDA aims to reduce the time and cost associated with bringing innovative digital health products to market.

This regulatory clarity fosters greater investment in the sector and accelerates the adoption of digital health technologies in healthcare delivery. The plan addresses the increasing demand for digital health solutions, including mobile apps, wearable sensors, and software-based diagnostics. These technologies are transforming patient care and healthcare management by enabling remote monitoring, personalized treatment recommendations, and improved patient engagement.

What Is the Future Outlook for SaMD Regulation?

The future of digital health regulation involves continued evolution of FDA policies to address emerging technologies. On March 15, 2024, the FDA published a paper titled "Artificial Intelligence and Medical Products" highlighting how CBER, CDER, CDRH, and OCP are working together on a coordinated approach to AI in medical products.

The FDA is expected to further refine its regulatory approach to ensure the safety and effectiveness of AI-driven digital health tools while promoting innovation. Global harmonization efforts also play a key role, with the FDA collaborating with international regulatory bodies through forums like the IMDRF to establish common standards and facilitate global adoption of digital health technologies.

Frequently Asked Questions

What is Software as a Medical Device (SaMD)?

Software as a Medical Device (SaMD) is software intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device, as defined by the International Medical Device Regulators Forum (IMDRF).

When was the FDA Digital Health Center of Excellence established?

What is a Predetermined Change Control Plan (PCCP)?

A Predetermined Change Control Plan (PCCP) allows manufacturers to describe anticipated modifications to AI/ML-enabled devices in their premarket submission, enabling iterative improvements without requiring additional submissions for each change.

How does the FDA regulate AI and machine learning in medical devices?

The FDA regulates AI/ML-enabled devices through the AI/ML-Based SaMD Action Plan released January 12, 2021, and final guidance on Predetermined Change Control Plans issued December 4, 2024, focusing on transparency, bias mitigation, and continuous monitoring.

What pathways does the FDA use for SaMD premarket review?

The FDA reviews SaMD through traditional pathways including 510(k) premarket notification, De Novo classification request, or Premarket Approval (PMA), depending on the device's risk classification and predicate availability.

Primary Sources

U.S. Food and Drug Administration. Digital Health Center of Excellence. Accessed 2026-06-09.
U.S. Food and Drug Administration. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. Released January 12, 2021.
U.S. Food and Drug Administration. Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions. Federal Register, December 4, 2024.
International Medical Device Regulators Forum. Software as a Medical Device (SaMD): Key Definitions. Accessed 2026-06-09.
U.S. Food and Drug Administration. Software as a Medical Device (SaMD). Accessed 2026-06-09.

Decision brief

Key questions this brief answers